Exchange: NASDAQ·Updated 05:55 PM EDT
BDTX logo

BDTX Black Diamond Therapeutics Inc

$2.27
$0.03
(1.34%)
Today
Closed $2.27
$0.00
(0.00%)
After Hours
Reported EarningsAug 5
Mkt Cap$128.7M
Vol491,257.00

About BDTX

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
41

Bearish Sentiment

How do you feel about BDTX?

Advertisement|Remove ads.